Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer

被引：0
|
作者：
Galsky, Matt D.
Krege, Susanne
Lin, Chia-Chin
Hahn, Noah M.
Ecke, Thorsten
Moshier, Erin L.
Sonpavde, Guru
Godbold, James H.
Oh, William K.
Bamias, Aristotelis
机构：
[1] Mt Sinai Sch Med, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY USA
[2] Alexianer Krefeld GmbH, Urol Klin, Krefeld, Germany
[3] Natl Taiwan Univ Hosp, Taipei, Taiwan
[4] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[5] HELIOS Hosp, Bad Saarow Pieskow, Germany
[6] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[7] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA
[8] HECOG, Athens, Greece
[9] Univ Athens, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.251
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
251
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer
    Gill, S.
    Berry, S.
    Biagi, J.
    Butts, C.
    Buyse, M.
    Chen, E.
    Jonker, D.
    Marginean, C.
    Samson, B.
    Stewart, J.
    Thirlwell, M.
    Wong, R.
    Maroun, J. A.
    [J]. CURRENT ONCOLOGY, 2011, 18 : S5 - S10
  • [2] Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma
    Martini, Alberto
    Fallara, Giuseppe
    Ploussard, Guillaume
    Pradere, Benjamin
    [J]. CURRENT OPINION IN UROLOGY, 2022, 32 (05) : 500 - 503
  • [3] Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials
    Petrelli, Fausto
    Coinu, Andrea
    Borgonovo, Karen
    Cabiddu, Mary
    Barni, Sandro
    [J]. HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2015, 14 (02) : 124 - 131
  • [4] Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials
    Fausto Petrelli
    Andrea Coinu
    Karen Borgonovo
    Mary Cabiddu
    Sandro Barni
    [J]. Hepatobiliary & Pancreatic Diseases International, 2015, 14 (02) : 124 - 131
  • [5] Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials
    Giessen, Clemens
    Laubender, Ruediger Paul
    Ankerst, Donna Pauler
    Stintzing, Sebastian
    Modest, Dominik Paul
    Mansmann, Ulrich
    Heinemann, Volker
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (01) : 225 - 235
  • [6] BEVACIZUMABIN AND FIRST-LINE CHEMOTHERAPY IN THE TREATMENT OF METASTATIC COLORECTAL CANCER: EVALUATION OF CLINICAL EFFICACY AND PROGRESSION-FREE SURVIVAL
    Liang, Jinhao
    Xiang, Chengjiang
    Sun, Ke
    [J]. FARMACIA, 2023, 71 (04) : 747 - 754
  • [7] Progression-Free Survival Remains Debatable Endpoint in Cancer Trials
    Tuma, Rabiya
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (21) : 1439 - 1441
  • [8] Progression-free survival as endpoint in metastatic RCC?
    Knox, Jennifer J.
    [J]. LANCET, 2008, 372 (9637): : 427 - 429
  • [9] Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/ HER2- metastatic breast cancer?
    Forsythe, Anna
    Chandiwana, David
    Barth, Janina
    Thabane, Marroon
    Baeck, Johan
    Shor, Anastasiya
    Tremblay, Gabriel
    [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1015 - 1025
  • [10] Real world progression-free survival in patients with advanced or metastatic urothelial cancer treated with first-line platinum-based chemotherapy
    Nikolaidis, Christos
    Li, Chen
    Lee, Chooi
    Mecke, Almut
    Reyes-Rivera, Irmarie
    Schroder, Carsten
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 319 - 319
12345